公开(公告)号：US20200263261A1

公开(公告)日：2020-08-20

申请号：US16867125

申请日：2020-05-05

Applicant: Genentech, Inc.

Inventor： Yinghui GUAN ,  Yasin SENBABAOGLU ,  Shannon TURLEY ,  Yulei WANG

IPC: C12Q1/6886 ,  G01N33/574 ,  A61K39/395

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), methods for selecting a therapy for an individual having cancer, methods of treating an individual having cancer, methods for assessing a response or monitoring the response of an individual to treatment with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), and related kits, anti-cancer therapies, and uses.

公开(公告)号：US20190085087A1

公开(公告)日：2019-03-21

申请号：US16192008

申请日：2018-11-15

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Luciana MOLINERO ,  Sanjeev MARIATHASAN ,  Shannon TURLEY ,  Jillian ASTARITA ,  Rafael CUBAS ,  Yagai YANG

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00

Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.

公开(公告)号：US20240011098A1

公开(公告)日：2024-01-11

申请号：US17901481

申请日：2022-09-01

Applicant: Genentech, Inc.

Inventor： Yinghui GUAN ,  Yasin SENBABAOGLU ,  Shannon TURLEY ,  Yulei WANG

IPC: C12Q1/6886 ,  A61K39/395 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61K39/39558 ,  G01N33/57488 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), methods for selecting a therapy for an individual having cancer, methods of treating an individual having cancer, methods for assessing a response or monitoring the response of an individual to treatment with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), and related kits, anti-cancer therapies, and uses.

公开(公告)号：US20230151103A1

公开(公告)日：2023-05-18

申请号：US17886809

申请日：2022-08-12

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Luciana MOLINERO ,  Sanjeev MARIATHASAN ,  Shannon TURLEY ,  Jillian ASTARITA ,  Rafael CUBAS ,  Yagai YANG

IPC: C07K16/28 ,  C12Q1/6886 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K16/2827 ,  C12Q1/6886 ,  G01N33/5743 ,  G01N33/57415 ,  G01N33/57492 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/75 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.